Dianthus Therapeutics
DNTH
72 hedge funds and large institutions have $174M invested in Dianthus Therapeutics in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 11 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
3% less funds holding
Funds holding: 74 → 72 (-2)
3.43% less ownership
Funds ownership: 73.98% → 70.55% (-3.4%)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
60% less capital invested
Capital invested by funds: $437M → $174M (-$263M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
Bleichroeder LP
New York
|
+$2.92M |
| 2 |
Renaissance Technologies
New York
|
+$1.97M |
| 3 |
Millennium Management
New York
|
+$1.28M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$613K |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
+$546K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$18.6M |
| 2 |
CC
Casdin Capital
New York
|
-$1.47M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$505K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$459K |
| 5 |
BlackRock
New York
|
-$438K |
DNTH Hedge Fund Activity: Q1 2020 in Review
72 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2020, worth a combined $174M — down 60% from $437M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of DNTH and 9 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 25 added.
The largest buyer was Bleichroeder LP, opening a new position worth an estimated $2.92M. The largest seller was Eventide Asset Management, cutting an estimated $18.6M.
- 72 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2020, down from 74 in Q4 2019.
- Funds reported $174M of Dianthus Therapeutics stock for Q1 2020, down 60% quarter-over-quarter.
- 9 funds opened new Dianthus Therapeutics positions in Q1 2020 and 11 closed out, a net change of -2 holders.
- The largest Dianthus Therapeutics buyer in Q1 2020 was Bleichroeder LP, an estimated $2.92M added.
- The largest Dianthus Therapeutics seller in Q1 2020 was Eventide Asset Management, an estimated $18.6M sold.
Based on aggregated 13F filings for Q1 2020.